Comparative effects of cyproterone acetate or a long-acting LHRH agonist in polycystic ovarian disease.

Schaison G, Couzinet B

Hormone research1 Jan 1987Cited by 1 (Europe PMC)

PMID2969860DOI10.1159/000180941PepBankPUB-02969860

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, triptorelin treatment produced marked clinical improvement, as did cyproterone acetate.
In plain wordsIn patients with polycystic ovarian disease, clinical symptoms improved during both triptorelin and cyproterone acetate treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseClinical improvement
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
Both treatments resulted in marked clinical improvement.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986001
02HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, triptorelin completely suppressed basal gonadotropins after 3 weeks.
In plain wordsIn patients with polycystic ovarian disease, triptorelin completely suppressed basal gonadotropins after 3 weeks.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBasal gonadotropins
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
In response to D-Trp6 LHRH, both basal and stimulated gonadotropin levels were completely suppressed after 3 weeks of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986002
03HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, triptorelin completely suppressed stimulated gonadotropins after 3 weeks.
In plain wordsIn patients with polycystic ovarian disease, triptorelin completely suppressed stimulated gonadotropins after 3 weeks.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseStimulated gonadotropins
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
In response to D-Trp6 LHRH, both basal and stimulated gonadotropin levels were completely suppressed after 3 weeks of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986003
04HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, ovarian steroids initially rose on day 2, then fell into the castrate range during triptorelin treatment.
In plain wordsIn patients with polycystic ovarian disease, ovarian steroids first rose with triptorelin, then fell into the castrate range.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
MixedOvarian steroids
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
After initial elevation on day 2, plasma ovarian steroid levels fell into the castrate range, without any change in dehydroepiandrosterone sulfate levels.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986004
05HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, triptorelin did not change dehydroepiandrosterone sulfate levels.
In plain wordsIn patients with polycystic ovarian disease, triptorelin did not change dehydroepiandrosterone sulfate levels.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeDehydroepiandrosterone sulfate
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
After initial elevation on day 2, plasma ovarian steroid levels fell into the castrate range, without any change in dehydroepiandrosterone sulfate levels.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986005
06HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, urinary 3 alpha-androstanediol excretion decreased significantly during triptorelin treatment.
In plain wordsIn patients with polycystic ovarian disease, urinary 3 alpha-androstanediol decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUrinary 3 alpha-androstanediol
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
Urinary 3 alpha-androstanediol excretion decreased significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986006
07HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, triptorelin inhibited gonadotropins more completely than cyproterone acetate.
In plain wordsIn patients with polycystic ovarian disease, triptorelin suppressed gonadotropins more completely than cyproterone acetate.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGonadotropin inhibition versus CPA
Study
n = 10
Comparator
Cyproterone acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
In patients with PCO, LHRH-A induced more complete gonadotropin inhibition than did CPA.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986007
08HumanRandomized controlled trialEfficacy outcome
In patients with polycystic ovarian disease, disease rapidly recurred after cessation of triptorelin, as after cyproterone acetate.
In plain wordsIn patients with polycystic ovarian disease, disease rapidly returned after triptorelin treatment stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseDisease recurrence after cessation
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg once a month · intramuscularAs given in this study (human).
Source sentences
Summary
However, following cessation of either therapy, the disease rapidly recurred.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO).
Report a problemFND-0296986008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.